Posted by Michael Wonder on 29 Nov 2021
Biosimilar industry vets critique Biden's drug pricing reforms
29 November 2021 - Specialty tiers for biosimilars and reforms that address the proliferation of poor quality patents would help lower costs and improve access, biosimilar industry veterans said.
Price negotiations for biologics and forcing drug manufacturers to rebate CMS for drug costs that exceed rates of general inflation are options the federal government is considering to control drug spending.
